

**REMARKS**


Claims 1-6 and 11-17 are presented in this application. Claims 7-10 and 18-21 have been canceled since they are presented in non-US format. Various claims as set forth above have been amended to place them in better form for US practice by removing multiple dependencies for the purpose of reducing fees and deleting reference to drawing elements.

Applicants have amended the specification for purposes of adding the priority information, and placing this section in more appropriate US form. Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Entry of the amendment prior to the examination of the application and calculation of the filing fee is respectfully requested.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,

  
\_\_\_\_\_  
Robert J. Smith  
Attorney for Applicant  
Registration No. 40,820

Date: June 1, 2006  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-9616  
Facsimile: 919-483-7988